Clinical Trial Update: A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase III study evaluating Dato-DXd with or without durvalumab vs investigator's choice of chemotherapy in combination with pembrolizumab for PD-L1 positive loc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)
• Durvalumab (durvalumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING